1.	Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 116428, 2012-003438-18, NCT01767467
2.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
3.	Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: BP-HM-001, NCT01744223
4.	Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCCC-102007-035, 102007-035, SCCC-02F07, NCT00621036
5.	A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Pro00001360, NCT00672152
6.	Host Dendritic Cells in Allograft Patients Phase: Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: 08-0906, NCT00935597
7.	Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: LS1081, NCI-2010-02003, 10-003023, NCT01239875